NASDAQ:APTX Aptinyx (APTX) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free APTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.09▼$0.1050-Day Range$0.06▼$0.1052-Week Range$0.01▼$0.72Volume231,100 shsAverage Volume1.32 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsInsider TradesOwnershipSocial MediaStock AnalysisEarningsInsider TradesOwnershipSocial Media Get Aptinyx alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Aptinyx Stock (NASDAQ:APTX)Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! APTX Stock News HeadlinesApril 23, 2024 | businesswire.comTentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEOMarch 12, 2024 | benzinga.comNew Leaf Venture Management III, L.L.C.'s Net WorthApril 28, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.February 9, 2024 | benzinga.comPatrick J Heron's Net WorthJanuary 13, 2024 | cnet.comBest Noise-Canceling Headphones for 2024December 17, 2023 | morningstar.comAptinyx Inc APTXSeptember 7, 2023 | morningstar.comNorth American Morning Briefing: Concerns About -2-March 30, 2023 | finance.yahoo.comHere's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock NowApril 28, 2024 | DTI (Ad)If you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! February 27, 2023 | finance.yahoo.comAptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate UpdateJanuary 31, 2023 | finance.yahoo.comAptinyx to Present at the SVB Securities Global Biopharma ConferenceJanuary 16, 2023 | ca.finance.yahoo.comAptinyx Inc. (APTX) Stock Historical Prices & Data - Yahoo FinanceJanuary 5, 2023 | fool.comAptinyx (NASDAQ: APTX)December 30, 2022 | insidermonkey.comAptinyx Inc. (NASDAQ:APTX) Q3 2022 Earnings Call TranscriptDecember 12, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)November 8, 2022 | finance.yahoo.comAptinyx Reports Third Quarter 2022 Financial Results and Recent HighlightsOctober 30, 2022 | fool.comAptinyx Inc. (NASDAQ: APTX)October 18, 2022 | finance.yahoo.comAptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022October 2, 2022 | reuters.comAPTX.OQ - Aptinyx Inc | Stock Price & Latest News | ReutersSeptember 24, 2022 | finance.yahoo.comAptinyx Inc. (APTX)September 12, 2022 | nasdaq.comHopeful week for insiders who might be regretting buying US$567k of Aptinyx Inc. (NASDAQ:APTX) stock earlier this year - NasdaqAugust 26, 2022 | marketscreener.comHC Wainwright Adjusts Price Target on Aptinyx to $1 From $2, Reiterates Buy Rating - Marketscreener.comAugust 25, 2022 | businesswire.comAptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies - Business WireAugust 25, 2022 | finance.yahoo.comAptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy BodiesAugust 22, 2022 | finance.yahoo.comBullish Aptinyx Inc. (NASDAQ:APTX) investors are yet to receive a pay off on their US$567k betAugust 19, 2022 | nasdaq.comBiotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates - NasdaqAugust 17, 2022 | morningstar.comNorth American Morning Briefing: Investors Seek -2- - MorningstarSee More Headlines Receive APTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:APTX CUSIPN/A CIK1674365 Webwww.aptinyx.com Phone(847) 871-0377FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book0.17Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.27 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 61)Principal Executive Officer, Fin. & Accounting Officer, President, Treasurer, Secretary and Director Mr. Patrick FlavinSenior Manager of Corporate Development & Investor RelationsMs. Molly DirVice President of Human ResourcesDr. Kathryn King Ph.D.Senior Vice President of Clinical & CMC OperationsMr. Tim NoffkeVP of Program Management & Chief of StaffDr. Harald Murck M.D.Ph.D., Vice President of Clinical & Medical AffairsMore ExecutivesKey CompetitorsContext TherapeuticsNASDAQ:CNTXGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPView All Competitors APTX Stock Analysis - Frequently Asked Questions How were Aptinyx's earnings last quarter? Aptinyx Inc. (NASDAQ:APTX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.31). During the same period in the prior year, the company earned ($0.24) earnings per share. What other stocks do shareholders of Aptinyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Kadmon (KDMN), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), ADMA Biologics (ADMA), DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX). When did Aptinyx IPO? Aptinyx (APTX) raised $77 million in an IPO on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. This page (NASDAQ:APTX) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptinyx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
